Propanc Receives Patent Approval in Key Jurisdiction
31 Agosto 2015 - 2:45PM
Access Wire
MELBOURNE, AUSTRALIA / ACCESSWIRE / August 31, 2015
/ Propanc Health Group Corporation (OTCQB: PPCH)
("Propanc" or "the Company"), an emerging healthcare company
focusing on development of new and proprietary treatments for
cancer patients suffering from pancreatic and colorectal cancers,
today announced that the Company's Australian patent application
covering its lead product PRP was accepted recently by the
Australian Patent Office.
The Australian patent application describes a pharmaceutical
composition for treating cancer comprising the proenzymes
trypsinogen and/or chymotrypsinogen, as well as several other
active agents disclosed in the patent.
Importantly, claims directed to compositions, as well as method
of treatment claims, were accepted by the Australian Patent Office.
This is considered a great result as composition claims are often
difficult to patent and are considered more valuable
commercially.
Propanc's lead patent application is now accepted or granted in
Australia, New Zealand and South Africa, and under examination in
key global regions such as the United States and European Union.
The Company expects the recent acceptance in Australia to support
ongoing applications in other territories under examination.
Propanc aims to fast track the development of proenzyme related
oncology products into clinical trials for colorectal and
pancreatic tumors initially. According to Global Analyst Reports,
the world market for colorectal cancer is expected to reach $8.8
billion by 2020 and the global pancreatic cancer market is
projected to exceed $1.2 billion by the year 2015.
"The Propanc management team are very pleased with our recent
patent acceptance in Australia," said James Nathanielsz, Propanc's
Chief Executive Officer. "The combined market for pancreatic and
colorectal cancers is around ten billion dollars and we believe PRP
could make a real difference for patients suffering from these
diseases. Establishing a first class intellectual property
portfolio is the cornerstone for supporting this vision."
About Propanc:
Propanc is currently focused on developing new cancer treatments
for patients suffering from pancreatic and colorectal cancers.
Propanc have developed a formulation of anti-cancer compounds which
exert a number of effects designed to control or prevent tumors
from recurring and spreading throughout the body. Propanc's
products involve or employ proenzymes, which are inactive
precursors of enzymes.
In the near term, Propanc intend to target patients with limited
remaining therapeutic options for the treatment of solid tumors
such as colorectal or pancreatic tumors. In future, Propanc intend
to development their lead product to treat (i) early stage cancer
and (ii) pre-cancerous diseases and (iii) as a preventative measure
for patients at risk of developing cancer based on genetic
screening. For more information, visit: www.propanc.com.
Forward-looking Statements:
Certain of the matters discussed in this announcement involve
risks and uncertainties including, without limitation, those
regarding the Company's ability to establish and maintain the
proprietary nature of its technology through the patent process,
its ability to license from others patents and patent applications,
if necessary, to develop certain products, its ability to implement
its long range business plan for various applications of its
technology, and its ability to enter into agreements with any
necessary marketing and/or distribution partners for purposes of
commercialization. This is not a solicitation to buy or sell
securities and does not purport to be an analysis of the company's
financial position. See Propanc's most recent Quarterly Report on
Form 10-Q and related 8K filings.
Contact:
Regal Consulting
Tel: 702 – 575 – 9157
SOURCE: Propanc Health Group Corporation
Grafico Azioni Propanc Biopharma (PK) (USOTC:PPCB)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Propanc Biopharma (PK) (USOTC:PPCB)
Storico
Da Giu 2023 a Giu 2024